During the Asia-focused Episode 37 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key trends from the 2026 Q2 Report: Global Trends in Biopharma Transactions, across China, Japan, and Korea.
China: Drove ~60% of first-half global licensing value, with the average deal nearing $3B and anchored by the $15B+ Bristol Myers Squibb–Hengrui collaboration. Venture financing posted a second straight billion-dollar-plus quarter ($1.2B) at a three-year high in deal volume.
Japan: The Nikkei hit fresh all-time highs, but biotech lagged and the IPO window paused with no offerings. Venture financing fell sharply, though GNI Group’s ~$278M acquisition of Ayumi Pharmaceutical provided a bright spot.
Korea: The KOSPI soared on the semiconductor cycle while biotech stayed flat. Venture financing eased to $88M across six early-stage deals, but Korea anchored a rebound in rest-of-world licensing to ~$6.1B across seven transactions.
Regional Takeaway: 2026 Q2 underscored Asia-Pacific’s rising centrality: China’s record out-licensing drove global deal value, Japan’s markets hit highs even as biotech lagged, and Korea kept building as an innovation hub.
Listen to the full episode, explore the complete 2026 Q2 report, and reach out to discuss what these trends mean for your strategy.
Podden och tillhörande omslagsbild på den här sidan tillhör
Biotalk. Innehållet i podden är skapat av Biotalk och inte av,
eller tillsammans med, Poddtoppen.
